Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$8.73 USD

8.73
7,216,354

+0.29 (3.44%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $8.72 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IOVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Iovance Biotherapeutics, Inc. [IOVA]

Reports for Purchase

Showing records 161 - 180 ( 187 total )

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

05/08/2019

Company Report

Pages: 6

1Q19 Results; Upcoming Inflection Points at ASCO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

04/03/2019

Daily Note

Pages: 4

Important Chess Moves to Head Regulatory Agencies off at the Pass

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

04/02/2019

Daily Note

Pages: 3

Iovance Officially Goes Pivotal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

04/01/2019

Daily Note

Pages: 4

TIL Persistence in Patients and Continued Case for Polyclonal Approach; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

02/28/2019

Company Report

Pages: 7

2018 results; Building the Foundation for TILs in Solid Tumors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

11/12/2018

Company Report

Pages: 11

SITC Updates Continue to Solidify Thesis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

10/12/2018

Company Report

Pages: 6

What We''ve All Been Waiting For, Plus RMAT and a Chunk of Cash; Price Target Raised to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

09/25/2018

Daily Note

Pages: 4

Updated Moffitt Lung Data in Intractable Population Point in Right Direction

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

09/21/2018

Industry Report

Pages: 5

Our Thoughts Post Investor Dinner Event With NSCLC KOL

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

09/06/2018

Company Report

Pages: 8

First Ever TIL Data in NSCLC Impress

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

08/07/2018

Company Report

Pages: 6

2Q18 Results; Watchful Waiting Ahead of FDA Meeting This Quarter; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

06/13/2018

Company Report

Pages: 6

Recent News in Space Supportive of Thesis, Not Recent Weakness; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

05/11/2018

Company Report

Pages: 6

Increased Momentum; Expanding Melanoma Study; Developing Next Gen Manufacturing

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

03/13/2018

Company Report

Pages: 6

2017 Results; Exciting Times Ahead for TILs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

02/08/2018

Company Report

Pages: 12

On the Road to Takeout; Profiling Continued Differentiation vs. CAR-T; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

01/25/2018

Company Report

Pages: 6

Nice Early Peek as the Plan Is Starting to Come Together; Target Boosted to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

01/17/2018

Company Report

Pages: 6

Regulatory Visibility and Hopefully Game Changing Data for Solid Tumors in 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

12/14/2017

Company Report

Pages: 16

2018 and TILs Should Strike a Nice Pose; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

11/13/2017

Company Report

Pages: 10

SITC Provides Some Real Answers for Important Upcoming Discussions; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Iovance Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

11/09/2017

Daily Note

Pages: 5

Initial Gen 2 Look Points In Right Direction for Process and Efficacy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party